Nuveen
RIGL icon

Nuveen’s Rigel Pharmaceuticals RIGL Stock Holding History

Nuveen’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.85M Sell
123,961
-213,466
-63% -$6.58M ﹤0.01% 2114
2026
Q1 		$9.12M Buy
337,427
+78,534
+30% +$2.64M ﹤0.01% 1611
2025
Q4 		$11.1M Buy
258,893
+125,426
+94% +$4.73M ﹤0.01% 1498
2025
Q3 		$3.78M Buy
133,467
+30,200
+29% +$903K ﹤0.01% 2038
2025
Q2 		$1.93M Sell
103,267
-11,951
-10% -$227K ﹤0.01% 2314
2025
Q1 		$2.07M Buy
115,218
+92,165
+400% +$1.87M ﹤0.01% 2325
2024
Q4 		$388K Sell
23,053
-92,110
-80% -$1.77M ﹤0.01% 3068
2024
Q3 		$1.86M Buy
+115,163
New +$1.35M ﹤0.01% 2447
2024
Q2 		– Sell
-322,335
Closed -$4.77M – 3401
2024
Q1 		$4.77M Buy
322,335
+75,668
+31% +$1.02M ﹤0.01% 2021
2023
Q4 		$3.58M Buy
246,667
+664
+0.3% +$6.79K ﹤0.01% 2127
2023
Q3 		$2.66M Buy
246,003
+275
+0.1% +$3.31K ﹤0.01% 2175
2023
Q2 		$3.17M Sell
245,728
-29,284
-11% -$396K ﹤0.01% 2136
2023
Q1 		$3.63M Buy
275,012
+3,386
+1% +$53.8K ﹤0.01% 2057
2022
Q4 		$4.08M Buy
271,626
+45,879
+20% +$421K ﹤0.01% 2027
2022
Q3 		$2.66M Sell
225,747
-83,817
-27% -$1.13M ﹤0.01% 2251
2022
Q2 		$3.5M Sell
309,564
-105,080
-25% -$2.11M ﹤0.01% 2159
2022
Q1 		$13.4M Sell
414,644
-36,324
-8% -$983K ﹤0.01% 1456
2021
Q4 		$12M Buy
450,968
+45,150
+11% +$1.36M ﹤0.01% 1587
2021
Q3 		$14.7M Sell
405,818
-10,885
-3% -$428K ﹤0.01% 1495
2021
Q2 		$18.1M Buy
416,703
+86,923
+26% +$3.28M 0.01% 1448
2021
Q1 		$11.3M Buy
329,780
+253,839
+334% +$10.1M ﹤0.01% 1726
2020
Q4 		$2.66M Sell
75,941
-2,157
-3% -$62.4K ﹤0.01% 2363
2020
Q3 		$1.87M Buy
78,098
+1,765
+2% +$43.3K ﹤0.01% 2417
2020
Q2 		$1.4M Buy
76,333
+16,059
+27% +$289K ﹤0.01% 2480
2020
Q1 		$941K Sell
60,274
-1,966
-3% -$41.8K ﹤0.01% 2536
2019
Q4 		$1.33M Hold
62,240
– – ﹤0.01% 2585
2019
Q3 		$1.16M Sell
62,240
-3,716
-6% -$76.8K ﹤0.01% 2633
2019
Q2 		$1.72M Buy
+65,956
New +$1.49M ﹤0.01% 2504

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen's RIGL Position: Q2 2026 in Review

Nuveen reduced its Rigel Pharmaceuticals (RIGL) stake by 63% in Q2 2026, selling an estimated $6.58M and leaving 123,961 shares worth $4.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2114.

Nuveen first reported a position in RIGL in Q2 2019 and has held it in 28 quarters since. The position peaked at $18.1M in Q2 2021. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Nuveen held 123,961 shares of Rigel Pharmaceuticals worth $4.85M as of Q2 2026.
  • Nuveen sold 213,466 Rigel Pharmaceuticals shares in Q2 2026, an estimated $6.58M.
  • Rigel Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2114 holding.
  • Nuveen first reported a position in Rigel Pharmaceuticals in Q2 2019 and has held it in 28 quarters since.
  • Nuveen's Rigel Pharmaceuticals position peaked at $18.1M in Q2 2021.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.